ArriVent BioPharma GAAP EPS of -$0.90 misses by $0.20

2 hours ago 1

ArriVent BioPharma press release (NASDAQ:AVBP): Q2 GAAP EPS of -$0.90 misses by $0.20.
Cash and investments of $254.5M as of June 30, 2025, in addition to $81.1M raised in the public offering in July 2025, expected to fund operating plan to mid-2027.

Recommended For You